Mitigate (Applied Research)
Abstract
The Mitigate Applied Research Project emphasizes the ability to conduct decontamination and medical actions that enable the quick restoration of combat power, maintain/recover essential functions that are free from the effects of Chemical, Biological, Radiological, and Nuclear (CBRN) hazards, and facilitate the return to pre-incident operational capability as soon as possible. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects have been restructured to align with the CBDP portfolio construct. MT2 efforts in FY 2022 remain in Projects CB2 and TM2. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts. Thrust Areas included in this Project are: (1) Biological Warfare Defense Therapeutics (2) Discovery of Medical Countermeasures Against New and Emerging (DOMANE) (3) Chemically Reactive Ocular Wound and Dermal Therapeutics (CROWD) (4) Emerging and Pharmaceutical-based Agent Threats (EMPATH) (5) Enabling Science (6) Reactivators of AChE as Therapeutics (ReACT) (7) Enhanced Survivability Coatings (8) Equipment Decontamination (9) Multifunctional Materials for Protection (10) Personnel Decontamination Biological Warfare Defense Therapeutics: Discovers broad-spectrum bacterial, toxin and viral therapeutics, and label expansion (repurposing) of medical countermeasures that are U.S. Food & Drug Administration (FDA) approved or in advanced stages of clinical development. These efforts are coordinated with Interagency and Department, to leverage public and force/defense health related investments made to minimize risk and speed approval of novel antibiotic countermeasures. DOMANE: Provides innovative and rapid medical countermeasures (MCMs) development capabilities that reduce developmental risks, cost and schedule associated with MCM fielding, and afford protection against and allow the Joint Force to rapidly respond to traditional, new and emerging biological warfare threat exposures to allow freedom of action. Chemically Reactive Ocular Wound and Dermal Therapeutics (CROWD): Develop a fielded medical countermeasure for the Warfighter that can treat a chemical agent that has breached the skin. Collect the data that the Food and Drug Administration (FDA) will require for approval. Emerging and Pharmaceutical-based Agent Threats (EMPATH): Assess candidate MCMs and transitions them to partner United States Government entities for development into fieldable drug products. Activities focus on assessing current therapeutic drugs for protection against opioid agents and developing MCMs to treat non-opioid sedatives. Enabling Science: Leverage technological advances and innovative approaches that will improve the time to develop and field chemical medical countermeasures (MCM) to the Warfighter. Modernize the chemical MCM development process to allow for an earlier assessment of both the safety and efficacy of candidate therapeutics before regulatory submission and to cultivate technologies that enable development efforts across other medical portfolios to improve the ability to conduct MCM testing more cost-effectively with fewer animals. Reactivators of AChE as Therapeutics (ReACT): Develops broad-spectrum, centrally-acting acetylcholinesterase (AChE) reactivators, that increase survival, reduce morbidity, and decrease neurological damage. Enhanced Survivability Coatings: Develops temporary coatings that resist chemical agent absorption and are quickly decontaminated in the field and allow the rapid regeneration of combat power. Equipment Decontamination: Addresses the limited capability to decontaminate personal equipment, weapons, vehicles, ships, and facilities; sensitive equipment, and hazardous waste. Efforts within this thrust seek to develop decontaminant formulations and procedures that reduce or eliminate residual contamination hazards, enable unit-level decontamination with rapid unmasking, reduce logistic needs, enable rapid sorting of clean from dirty to rapidly return high-value equipment to normal use, and to develop improved test methods. Multifunctional Materials for Protection: Discovers, develops, and integrates novel, reactive/catalytic materials and scale material manufacturing with maximum sorption and reactivity, and characterize materials using state-of-the-art in operando and ambient pressure spectroscopies, for eventual integration into next generation decontaminants that reactively decontaminate chemical warfare agents. Personnel Decontamination: Develops personnel decontaminants with lower lifecycle costs and storage constraints and determines time, efficacy, and logistics burdens to Warfighters for mass casualty decontamination.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2024
- Source ID
- MT2_0602384BP_2_0400_PB_2024
Related Documents
- Root: Chemical and Biological Defense Program
- Child Accomplishment: 1) Biological Warfare Defense Therapeutics
- Child Accomplishment: 2) Discovery of Medical Countermeasures Against New and Emerging (DOMANE)
- Child Accomplishment: 3) Chemical Reactive Ocular Wound and Dermal Therapeutics (CROWD)
- Child Accomplishment: 4) Emerging and Pharmaceutical-based Agent Threats (EMPATH)
- Child Accomplishment: 5) Enabling Science
- Child Accomplishment: 6) Reactivators of AChE as Therapeutics (ReACT)
- Child Accomplishment: 7) Enhanced Survivability Coatings
- Child Accomplishment: 8) Equipment Decontamination
- Child Accomplishment: 9) Multifunctional Materials for Protection
- Child Accomplishment: 10) Personnel Decontamination